Summary of the Article: Bariatric Surgery Remains Effective Across Socioeconomic Levels for Type 2 Diabetes
This article from STAT News discusses a recent study reinforcing the effectiveness of bariatric surgery for treating type 2 diabetes and obesity, even when considering social determinants of health. Here’s a breakdown of the key points:
* Patti’s Expertise: Dr. patti is an endocrinologist leading long-term clinical trials comparing bariatric surgery to medical management for type 2 diabetes. She emphasizes the importance of considering social vulnerability (income, food security, healthcare access) in treatment choices, as these factors contribute to the growth of the disease.
* Superiority of Surgery: A 2024 trial demonstrated bariatric surgery’s superiority over medication and lifestyle changes,showing lower blood glucose,greater weight loss,reduced medication use,diabetes remission,and improved cardiovascular risk factors.
* New Analysis & Key Finding: A secondary analysis of the larger trial,published in the Annals of Internal Medicine,found that bariatric surgery was more effective than medical therapy irrespective of a patient’s socioeconomic background. This challenges the notion that surgery is only beneficial for those with resources to maintain lifestyle changes.
* Study Details: The original trial involved 355 participants across four US cities, comparing surgery (gastric bypass, sleeve gastrectomy, lap band) to medical therapy including nutrition counseling and exercise. The study evolved over 12 years with changes in surgical preferences (lap band falling out of favor) and the increasing availability of new obesity drugs (GLP-1s).
* Drug Use & Crossover: Participants sometimes switched between treatment groups (medical to surgical, or vice versa), and many eventually incorporated incretin-based therapies (like Ozempic/Wegovy/Mounjaro) into their treatment plans.
* Patti’s Conclusion: Despite the rise of effective medications like GLP-1s, Patti argues that bariatric surgery remains an underutilized and durable therapy for type 2 diabetes and obesity.
Related Article: The article also links to a related STAT News piece discussing the decrease in demand for bariatric surgery as GLP-1 drugs become more popular.
In essence, the article highlights that bariatric surgery offers a significant and consistent benefit for individuals with type 2 diabetes and obesity, even those facing socioeconomic challenges, and should remain a considered treatment option alongside newer medications.
